US 12,139,755 B2
Methods of RNA amplification
Gary J. Latham, Austin, TX (US); Richard Andrew Blidner, Austin, TX (US); and Liangjing Chen, Austin, TX (US)
Assigned to ASURAGEN, INC., Austin, TX (US)
Filed by ASURAGEN, INC., Austin, TX (US)
Filed on Dec. 20, 2021, as Appl. No. 17/556,387.
Application 17/556,387 is a continuation of application No. 16/478,705, granted, now 11,236,384, previously published as PCT/US2018/013830, filed on Jan. 16, 2018.
Claims priority of provisional application 62/448,371, filed on Jan. 19, 2017.
Prior Publication US 2022/0177949 A1, Jun. 9, 2022
Int. Cl. C12Q 1/68 (2018.01); C12N 9/12 (2006.01); C12Q 1/6844 (2018.01); C12Q 1/686 (2018.01)
CPC C12Q 1/686 (2013.01) [C12N 9/1276 (2013.01); C12Q 1/6846 (2013.01); C12Q 2521/107 (2013.01); C12Q 2527/125 (2013.01); C12Q 2531/101 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A kit for improving cDNA synthesis by linear amplification of an RNA template, said kit comprising:
a reaction volume containing buffer, dNTPs, betaine or a betaine analog in an amount of about 0.75 to about 3.5 M, and a first primer complementary to an RNA template; and
a thermostable reverse transcriptase capable of synthesizing cDNA by linear amplification of the RNA template;
wherein at least one cycle of cDNA synthesis includes an extension temperature and a denaturation temperature; and
wherein the denaturation temperature is about 75 degrees C. to 90 degrees C.